Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias

Acta Oncol. 2010;49(1):109-10. doi: 10.3109/02841860903302913.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / pathology
  • Carcinoma / therapy
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Cetuximab
  • Combined Modality Therapy
  • Dasatinib
  • Ear Diseases / pathology
  • Ear Diseases / therapy
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Keratoacanthoma / pathology
  • Keratoacanthoma / therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Neoplasms, Second Primary / pathology
  • Neoplasms, Second Primary / therapy*
  • Pyrimidines / administration & dosage
  • Radiotherapy*
  • Scalp / pathology
  • Thiazoles / administration & dosage
  • Tongue Neoplasms / pathology
  • Vocal Cords / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Pyrimidines
  • Thiazoles
  • Fusion Proteins, bcr-abl
  • Cetuximab
  • Dasatinib